Occurrence and Bacterial Performance of Leclercia Adecarboxylata Isolated from Lung Infections

Abstract Background: This current study designed for isolation and identification of Leclercia adecarboxylata from patients infected with different types of lung infections in Baghdad Teaching Hospital of Medical City by Department of Medical Laboratory Techniques of Al-Rafidian College University during the period from December 2022 to March 2023. Materials and Methods: Specimen of sputum and bronchial fluid were collected from 200 patients including both sexes with different ages, who suffered from lung infections that clinically diagnosed by the consultants. These 200 specimen were assessed directly after inoculation on the proper media for isolation and identification. Correspondingly, the identification was confirmed by API 20 system (Biomeriux Company, France), Vitek 2 system and 16S rRNA gene sequencing. Antimicrobial susceptibility profile of Leclercia adecarboxylata was patterned against many types of antibiotics that used for treatment of lung infections such as Amoxicillin, Fluoroquinolones, Cephalosporin, Piperacillin, Clindamycin, Erythromycin, Levofloxacin, Linezolid, Imipenem, Trimethoprim/ Sulfamethoxazole (SMX-TMP), Vancomycin, Fosfomycin. Results: Results showed polymicrobial distribution of 8 types of pathogenic bacterial isolates in 163 out of 200 specimens these were Klebsilla pneumoniae 27 (16.56%), Acinetobacter baumannii 25 (15.33%), Staphylococcus aureus 23 (14.11%), Streptococcus pneumoniae and Escherichia coli 20 (12.26%) for each one, 19 (11.65%), isolates for Streptococcus pyogenes and Haemophilus influenzae and 10 (6.13%) Leclercia adecarboxylata isolates. Conclusion: Antimicrobial susceptibility pattern of L. adecarboxylata isolates presented multidrug resistance through high susceptibility (100%) for Amoxicillin, Fluoroquinolones, Cephalosporin, Piperacillin, Erythromycin and Imipenem. Also it was susceptible to Levofloxacin (90%), Clindamycin and Trimethoprim/Sulfamethoxazole (SMX-TMP) (80%), Linezolid (50%) and Vancomycin (10%).